CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML)
Latest Information Update: 16 Jun 2022
At a glance
- Drugs Crisantaspase (Primary) ; Cytarabine (Primary) ; Daunorubicin (Primary) ; Etoposide (Primary) ; Gemtuzumab ozogamicin (Primary) ; Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms CHOA-AML
Most Recent Events
- 15 Jul 2021 Status changed from active, no longer recruiting to discontinued.
- 07 Jun 2021 Planned End Date changed from 1 Jan 2022 to 1 Aug 2021.
- 07 Jun 2021 Planned primary completion date changed from 1 Jan 2022 to 1 Aug 2021.